What question did this study set out to answer?

To determine whether recombinant human neuregulin-1 attenuates pulmonary vascular and right ventricular remodeling and dysfunction in experimental pulmonary arterial hypertension.

October 26, 2015Cardiovascular ResearchOpen Access

Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension

View Full Paper

Ask AI

Bookmark

Why the study?

Does rhNRG-1 treatment attenuate pulmonary arterial and RV remodelling and dysfunction in a rat model of MCT-induced PAH?

Population

Rat model of monocrotaline-induced pulmonary arterial hypertension and pressure-overloaded right ventricle

Design

Preclinical

Authors

PMPedro Mendes‐FerreiraUniversidade do Porto CMC. Maia-RochaUniversidade do Porto RARui AdãoHeart Failure & Transplant

Discussion

Member takes

Implication

Caution against clinical use of rhNRG-1 in PAH; extends preclinical data but leaves open human translation.

Key Points

To determine whether recombinant human neuregulin-1 attenuates pulmonary vascular and right ventricular remodeling and dysfunction in experimental pulmonary arterial hypertension.
Administered recombinant human neuregulin-1 (rhNRG-1) in a rat model of monocrotaline (MCT)-induced pulmonary arterial hypertension.
Evaluated functional and structural remodeling parameters in both the pulmonary arterial vasculature and the pressure-overloaded right ventricle.
rhNRG-1 treatment attenuated pulmonary arterial remodeling and right ventricular dysfunction in monocrotaline-treated rats.
Therapy exerted direct anti-remodeling effects on the pressure-overloaded right ventricle.

Structured PICO

Does rhNRG-1 treatment attenuate pulmonary arterial and RV remodelling and dysfunction in a rat model of MCT-induced PAH?

Population

Rat model of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) and pressure-overloaded right ventricle (RV)

Intervention

Recombinant human neuregulin-1 (rhNRG-1) treatment

Outcome

Pulmonary arterial and RV remodelling, and dysfunctionsurrogate

rhNRG-1 demonstrates potential therapeutic benefits for pulmonary arterial hypertension by attenuating right ventricular remodeling and dysfunction in a preclinical model.

Cite This Study

Mendes‐Ferreira et al. (2015) studied this question.

synapsesocial.com/papers/69d8f7181ab91f1400beddd5 https://doi.org/10.1093/cvr/cvv244

View Full Paper

Ask AI

Bookmark

Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider